Federal Register: December 22, 2006 (Volume 71, Number 246)
DOCID: FR Doc E6-21895
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
NOTICE: NOTICES
ACTION: Applications, hearings, determinations, etc.:
SUBJECT CATEGORY:
Importer of Controlled Substances Notice of Registration
DOCUMENT SUMMARY:
By Notice dated July 19, 2006, and published in the Federal Register on July 26, 2006, (71 FR 42417), Meridian Medical Technologies, 255 Hermelin Drive, St. Louis, Missouri 63144, made application to the Drug Enforcement Administration (DEA) to be registered as an importer of Morphine (9300), a basic class of controlled substance listed in schedule II.
The company plans to import products for research experimentation or clinical use and analytical testing.
One objection was received; however, it has subsequently been
withdrawn. DEA has considered the factors in 21 U.S.C. Sec. 823(a) and
Sec. 952(a) and determined that the registration of Meridian Medical
Technologies to import the basic class of controlled substances is
consistent with the public interest and with United States obligations
under international treaties, conventions, or protocols in effect on
May 1, 1971, at this time. DEA has investigated Meridian Medical
Technologies to ensure that the company's registration is consistent
with the public interest. The investigation has included inspection and
testing of the company's physical security systems, verification of the
company's compliance with state and local laws, and a review of the
company's background and history. Therefore, pursuant to 21 U.S.C.
Sec. 952(a) and Sec. 958(a), and in accordance with 21 CFR Sec.
1301.34, the above named company is granted registration as an importer of the basic class of controlled substances listed.
Dated: December 14, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. E621895 Filed 122106; 8:45 am]
BILLING CODE 441009P
SUMMARY:
Meridian Medical Technologies,
DOCUMENT BODY 2:
By Notice dated July 19, 2006, and published in the Federal Register on July 26, 2006, (71 FR 42417), Meridian Medical Technologies, 255 Hermelin Drive, St. Louis, Missouri 63144, made application to the Drug Enforcement Administration (DEA) to be registered as an importer of Morphine (9300), a basic class of controlled substance listed in schedule II.
The company plans to import products for research experimentation or clinical use and analytical testing.
One objection was received; however, it has subsequently been
withdrawn. DEA has considered the factors in 21 U.S.C. Sec. 823(a) and
Sec. 952(a) and determined that the registration of Meridian Medical
Technologies to import the basic class of controlled substances is
consistent with the public interest and with United States obligations
under international treaties, conventions, or protocols in effect on
May 1, 1971, at this time. DEA has investigated Meridian Medical
Technologies to ensure that the company's registration is consistent
with the public interest. The investigation has included inspection and
testing of the company's physical security systems, verification of the
company's compliance with state and local laws, and a review of the
company's background and history. Therefore, pursuant to 21 U.S.C.
Sec. 952(a) and Sec. 958(a), and in accordance with 21 CFR Sec.
1301.34, the above named company is granted registration as an importer of the basic class of controlled substances listed.
Dated: December 14, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. E621895 Filed 122106; 8:45 am]
BILLING CODE 441009P